Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Diagnocure CUR -- Ignore unavailable to you. Want to Upgrade?

To: Benfica who wrote (81)	7/30/2000 2:00:10 PM
From: john.d	Respond to of 132

<do you know why this stock has dropped under 2 dollars?> Earlier this year the company received FDA approval for their ImmunoCyt bladder cancer test. The test was approved for use in Canada in 97 and also in Europe a few years ago but not sure of the year. There has been no mention of sales of this product in their latest annual report or the last quarterly report. Therefore one can only assume that the sales are extremely weak or nonexistent. I do understand that the test is more accurate than alternatives but this has not translated into sales. Until they demonstrate sales I think the stock will continue to be weak. I think our only hope this year is for the company to make a significant announcement on the prostate cancer test. John

To: Benfica who wrote (81)	8/2/2000 7:14:26 PM
From: Robert Dirks	Read Replies (1) \| Respond to of 132

All I can say is I think this is an excellent stock with great prospects, but the CDN market doesn't care. I may have made a mistake, but im out at 2.25 and just waiting for lower prices late this year. I expect a sizable market correction into late this year, and want to hold zero until well into the carniage. CUR needs a deal with a major player, otherwise the market will walk all over them no matter how much their great product can help patients. They need an NASD partner with big reach. Thats the way I see it for now......... RD